SynthesisSleep & breathing = Schlaf & Atmung2026
Benzodiazepines or related drugs and risk of cardiovascular diseases: a meta-analysis of cohort studies.
Synthesis in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBenzodiazepines and related drugs (BZRDs) are widely prescribed for insomnia, anxiety, and other psychiatric disorders. However, their cardiovascular safety remains insufficiently characterized. This meta-analysis systematically evaluated the association between BZRD use and the risk of cardiovascular disease (CVD).
methodsWe systematically searched PubMed, Embase, and the Library database from inception to Jan 2026, to identify relevant cohort studies. A random effects model was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between BZRD use and CVD risk. Heterogeneity among studies was assessed using I2 statistics.
resultsA total of 9 studies involving 11,509,700 individuals were included. BZRD use was associated with an increased risk of CVD (pooled odds ratio [OR], 1.40; 95% confidence interval [CI], 1.17–1.69). This association remained unchanged (pooled OR, 1.40; 95% CI, 1.31–1.48) when analyses accounted for drug indications. Regarding the CVD outcome, the results of the sensitivity and subgroup analyses confirmed the stability of the findings. Subgroup analysis based on CVD types revealed that the use of BZRD increased the risk of heart rhythm disorder (HRD) (OR, 2.44; 95% CI, 1.14–5.22), and ischemic heart disease (IHD) (OR, 1.15; 95% CI, 1.13–1.18), but did not elevate the risk of stroke (OR, 1.08; 95% CI, 0.98–1.2) or heart failure (HF) (OR, 1.27; 95% CI, 0.81–1.98).
conclusionThis meta-analysis supports an association between BZRD use and an increased risk of CVD. Future well-designed studies are warranted to examine the impact of treatment duration, dosage, and specific BZRD agents on CVD risk.
Indexed as
Identifiers
41688796What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.